Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pulmocod is a combination pharmaceutical product developed and marketed by Stadmed, primarily used for the symptomatic relief of dry (non-productive) cough. It contains two active ingredients: codeine phosphate and chlorpheniramine maleate. Codeine phosphate is an opioid analgesic that acts as a centrally acting antitussive by suppressing the cough reflex in the medulla oblongata. Chlorpheniramine maleate is a first-generation antihistamine that blocks H1 receptors, helping to reduce allergic symptoms and providing a mild sedative effect that can assist in nighttime cough management. As a marketed generic formulation in India, it is typically available as an oral syrup.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on codeine phosphate + chlorpheniramine maleate.